1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Netherland

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Netherland
TABLE OF CONTENTS
NETHERLANDS 1
HEALTHCARE SYSTEM.1
Facts and Figures1
Market Indicators..2
Provision and Funding..4
Basic Health Insurance4
Supplementary Health Insurance5
Long-term Care.5
Healthcare Funding..6
Healthcare Providers.6
PRICING.6
Prescription Drugs.6
WGP Methodology.6
WGP Price Revisions..7
WGP Reforms.7
Pricing Agreements..7
Generic Drugs.7
Hospital Drugs8
OTC Drugs.8
REIMBURSEMENT8
Admission to Reimbursement..8
Pre-assessment Process8
Reimbursement Applications..9
Reimbursement Process10
Price-Volume Agreements11
Other Pricing Agreements11
Provisional Reimbursement.12
Reimbursement Categories..12
IMS PHARMACEUTICAL PRICING and REIMBURSEMENT CONCISE GUIDE SWITZERLAND TABLE OF CONTENTS
IMS Pharmaceut ical Pr ic ing and Reimbursement Conc ise Guide v
Reimbursement Prices..13
Reference Price System13
Preference Policy Scheme.13
Hospital Reimbursement..15
Reimbursement Process15
Reassessments..15
Pricing Agreements..16
Formularies16
DRG System17
DRG Add-on Drugs.17
Specialist Drugs for Hospital Out-patients.18
Changes in Reimbursement Status.19
Retail Sector..19
Hospital Sector..19
Changes in Reimbursement Prices..20
Maximum Prices20
Reference Prices20
Preference Policy..20
Pricing Agreements..20
PHARMACOECONOMICS..21
Pharmacoeconomic Requirements..21
Mandatory Requirement..21
Exemptions21
Pharmacoeconomic Guidelines21
Hospital Drugs ..22
Provisional Reimbursement.22
PRICE BUILD UP..22
Wholesalers.22
Margins..22
Background23
Retail Pharmacies..23
vi IMS Pharmaceut ical Pr icing and Reimbursement Concise Guide
Pharmacy Remuneration.23
Discounts24
Clawback24
Background24
OTC Sales25
E-pharmacy25
Dispensing Doctors25
Sales Tax..25
COST CONTAINMENT26
Industry Paybacks.26
Promotional Costs..26
Patient Co-payments.26
Mandatory Deductible..26
Other Charges27
Prescribing Controls..27
Treatment Guidelines27
Targets27
Analysis of Prescribing Habits.28
Electronic Prescribing Systems28
Other Information for Prescribers..28
Generics..29
Market29
INN Prescribing.29
Substitution..29
Rx-to-OTC Switches29
Switching Process.29
OTC Market.30
Parallel Trade..30
FUTURE DEVELOPMENTS31
Outlook31
NAMES and ADDRESSES.31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.